About Sinfonia Biotherapeutics

Sinfonia Biotherapeutics is a clinical stage company motivated by the need to transform the treatments of patients suffering from pain and devastating neurological diseases.

Building on an innovative tradition in science with deep roots in the Karolinska institute, we develop next generation biotherapeutics.

We have footprints in both Sweden and US to facilitate our global presence, research collaborations, and partnering to deliver value for patients and investors

Our Leadership Team

Lars Wahlberg, MD, PhD

CEO/CMO

Neurosurgeon, translational scientist, and entrepreneur 

>20 years of biotechnology R&D experience in developing biologics-based therapies for neurological disorders 

Johan Lundkvist, As. Prof

COO/CSO

Neurobiologist and cellbiologist by training

Associate Professor at Karolinska Institute in 2005

>17 years industrial leadership  experience from small biotech start-ups  and large pharma within neurological disorders

An van Es-Johansson, MD

Head Clinical Development

Physician , entrepreneur with extensive Board experience

> 30 years international experience in big pharma and biotech companies with focus on Clinical Development, Regulatory and Pharmacovigilance

Bob Blomquist

Corporate Development

Business leader with operational experience in Fortune 500 and new venture startups

>35 years of healthcare industry experience, including biopharmaceuticals, diagnostics and medical devices

Advisor to private equity and biopharma

Kristofer Svensson, B.Sc

CFO

B.Sc in Business Administration and Economics

 Held several executive finance positions in the medtech field Since 2017.

Thomas Pollare, MD, PhD

Chairman

Experienced advisor and investor, including  partner and member of 3i Global Healthcare team

 > 25 years health care industry experience with several executive positions in major pharma companies and smaller biotechs

Experience from over 30 board positions